A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
MD Anderson Study Status
Nivolumab, Ipilimumab, Cabazitaxel, Prednisone
The purpose of this study is to determine whether Nivolumab plus Ipilimumab has preliminary evidence of safety and effectiveness in the treatment of participants with metastatic castration-resistant prostate cancer who have progressed after prior Docetaxel-containing regimen.
Information and next steps
Genitourinary Medical Oncology
For general questions about clinical trials: